REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, November 6, 2025 at 8:00 a.m. ET to discuss third quarter financial results for the period ended September 30, 2025 and operational highlights.

Listeners can register for a live webcast via the company website, analysts may use a separate link to join the Q&A, and a replay will be available on the investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes early.

ROCKVILLE, Md., Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2025, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2025-financial-results-and-operational-highlights-302598006.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) discuss Q3 2025 results?

The company will hold a conference call on November 6, 2025 at 8:00 a.m. ET to discuss Q3 2025 results.

What period do the Q3 2025 results cover for REGENXBIO (RGNX)?

The results cover the quarter ended September 30, 2025.

How can I listen to the REGENXBIO (RGNX) November 6, 2025 conference call webcast?

Listeners can register and access the live webcast via the company's investor website using the provided registration link.

Can analysts ask questions during the REGENXBIO (RGNX) Q3 2025 call?

Yes; analysts who wish to participate in the Q&A should use the separate analyst link provided by the company.

Will a replay of the REGENXBIO (RGNX) November 6, 2025 call be available?

Yes; a replay will be posted on the investor website approximately two hours after the call ends.

Is there a recommended arrival time for the REGENXBIO (RGNX) webcast?

The company advises participants to join the webcast 15 minutes prior to the scheduled start time.